Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

References

• International Diabetes FederationIDF Diabetes Atlas7th edBrusselsIDF2015
   Google Scholar
• CheungBMOngKLChernySSShamPCTsoAWLamKSDiabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006Am J Med2009122544345319375554
   PubMed Web of Science ®Google Scholar
• GuoXHThe value of short-and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatideCurr Med Res Opin2016321617626439329
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAdherence to Long-Term Therapies: Evidence for ActionGenevaWHO2003
   Google Scholar
• AscheCLaFleurJConnerCA review of diabetes treatment adherence and the association with clinical and economic outcomesClin Ther20113317410921397776
   PubMed Web of Science ®Google Scholar
• HansenRAFarleyJFDroegeMMaciejewskiMLA retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005Clin Ther20103271308131920678679
   PubMed Web of Science ®Google Scholar
• AyyagariRWeiWChengDPanCSignorovitchJWuEQEffect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatmentValue Health201518219820525773555
   PubMed Web of Science ®Google Scholar
• ChangPYChienLNLinYFChiouHYChiuWTNonadherence of oral antihyperglycemic medication will increase risk of end-stage renal diseaseMedicine (Baltimore)20159447e205126632708
   PubMed Web of Science ®Google Scholar
• de GalanBEInsulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectivesPatient Prefer Adherence2016102097210627799746
   PubMed Web of Science ®Google Scholar
• TibaldiJMEvolution of insulin: from human to analogAm J Med201412710S25S38
   Web of Science ®Google Scholar
• SegalARVootlaTBeaserRSInsulin: making sense of current optionsEndocrinol Metab Clin North Am201645484587427823608
   PubMed Web of Science ®Google Scholar
• CliffordSPerez-NievesMSkalickyAMReaneyMCoyneKSA systematic literature review of methodologies used to assess medication adherence in patients with diabetesCurr Med Res Opin20143061071108524432796
   PubMed Web of Science ®Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• García-PérezLEAlvarezMDillaTGil-GuillénVOrozco-BeltránDAdherence to therapies in patients with type 2 diabetesDiabetes Ther20134217519423990497
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• KrassISchiebackPDhippayomTAdherence to diabetes medication: a systematic reviewDiabet Med201532672573725440507
   PubMed Web of Science ®Google Scholar
• OdegardPSCapocciaKMedication taking and diabetes a systematic review of the literatureDiabetes Educ20073361014102918057270
   PubMed Web of Science ®Google Scholar
• SapkotaSBrienJAGreenfieldJAslaniPA systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes: impact on adherencePLoS One2015102e011829625710465
   PubMed Web of Science ®Google Scholar
• EgedeLEGebregziabherMEcholsCLynchCPLongitudinal effects of medication nonadherence on glycemic controlAnn Pharmacother201448556257024586059
   PubMed Web of Science ®Google Scholar
• IglayKCartierSERosenVMMeta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetesCurr Med Res Opin20153171283129626023805
   PubMed Web of Science ®Google Scholar
• PeyrotMBarnettAHMeneghiniLFSchumm-DraegerPMFactors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetes Obes Metab201214121081108722726104
   PubMed Web of Science ®Google Scholar
• CarlsGTuttleETanRDDifferences in T2DM therapy outcomes in trials vs. the real-world (RW): identifying the impact of poor adherence. Late Breaking AbstractsPoster presented at: 76th Scientific Sessions of the American Diabetes AssociationJune 10–14, 2016New Orleans, LA
   Google Scholar
• BrownMTBussellJKMedication adherence: WHO cares?Mayo Clin Proc201186430431421389250
   PubMed Web of Science ®Google Scholar
• MarzecLNMaddoxTMMedication adherence in patients with diabetes and dyslipidemia: associated factors and strategies for improvementCurr Cardiol Rep2013151141824057772
   PubMed Web of Science ®Google Scholar
• OdegardPSGraySLBarriers to medication adherence in poorly controlled diabetes mellitusDiabetes Educ200834469269718669811
   PubMed Web of Science ®Google Scholar
• NauDPRecommendations for improving adherence to type 2 diabetes mellitus therapy: focus on optimizing oral and non-insulin therapiesAm J Manag Care2012183 SupplS49S5422558942
   PubMedGoogle Scholar
• TivMVielJFMaunyFMedication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based studyPLoS One201273e3241222403654
   PubMed Web of Science ®Google Scholar
• ReachGPechtnerVGentilellaRCorcosACerielloAClinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitusDiabetes Metab201743650151128754263
   PubMed Web of Science ®Google Scholar
• OwensDRMonnierLBarnettAHFuture challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapyDiabetes Obes Metab201719101339135228432748
   PubMed Web of Science ®Google Scholar
• AdamsASTrinactyCMZhangFMedication adherence and racial differences in A1C controlDiabetes Care200831591692118235050
   PubMed Web of Science ®Google Scholar
• PladevallMWilliamsLKPottsLADivineGXiHLafataJEClinical outcomes and adherence to medications measured by claims data in patients with diabetesDiabetes Care200427122800280515562188
   PubMed Web of Science ®Google Scholar
• CobdenDLeeWCBaluSJoshiAVPashosCLHealth outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitusPharmacotherapy200727794896217594200
   PubMed Web of Science ®Google Scholar
• HoPMRumsfeldJSMasoudiFAEffect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitusArch Intern Med2006166171836184117000939
   PubMed Web of Science ®Google Scholar
• BoyeKSGarcia-PerezLECurtisSLageMJAssociation between adherence to glucose-lowering agents and outcomes among patients age = 65 with type 2 diabetesPoster presented at: 76th Scientific Sessions of the American Diabetes AssociationJune 10–14, 2016New Orleans, LA
   Google Scholar
• CurtisSBoyeKSLageMJIncreased adherence to glucose-lowering agents is associated with improvements in acute care outcomesPoster presented at: 76th Scientific Session of the American Diabetes AssociationJune 10–14, 2016New Orleans, LA
   Google Scholar
• JuarezDTTanCDavisJMauMFactors affecting sustained medication adherence and its impact on healthcare utilization in patients with diabetesJ Pharm Health Serv Res201342899423717343
   PubMedGoogle Scholar
• NguyenHCappellKNelsonJChuBCJohnstonSRetrospective study of the association between adherence to glucagon-like peptide-1 receptor agonist therapy and hospitalization risk and costsPoster presented at: 76th Scientific Sessions of the American Diabetes AssociationJune 10–14, 2016New Orleans, LA
   Google Scholar
• BuysmanEKLiuFHammerMLangerJImpact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort studyAdv Ther201532434135525832470
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• KrukMESchwalbeNThe relation between intermittent dosing and adherence: preliminary insightsClin Ther200628121989199517296456
   PubMed Web of Science ®Google Scholar
• ReckerRRGallagherRMacCosbePEEffect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of womenMayo Clin Proc200580785686116007889
   PubMed Web of Science ®Google Scholar
• PolonskyWHFisherLHesslerDBruhnDBestJHPatient perspectives on once-weekly medications for diabetesDiabetes Obes Metab2011132144149
   PubMed Web of Science ®Google Scholar
• CuddihyRMBorgmanSKConsiderations for diabetes: treatment with insulin pen devicesAm J Ther201320669470221768872
   PubMed Web of Science ®Google Scholar
• DaviesMJGagliardinoJJGrayLJKhuntiKMohanVHughesRReal-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic reviewDiabet Med201330551252423323988
   PubMed Web of Science ®Google Scholar
• DoggrellSAChanVAdherence to insulin treatment in diabetes: can it be improved?J Diabetes20157331532125195971
   PubMed Web of Science ®Google Scholar
• GaddiAVBenedettoDCapelloFOral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimensPublic Health20141281707623969148
   PubMed Web of Science ®Google Scholar
• HanSIglayKDaviesMJZhangQRadicanLGlycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysisCurr Med Res Opin201228696997722494018
   PubMed Web of Science ®Google Scholar
• KirkmanMSRowan-MartinMTLevinRDeterminants of adherence to diabetes medications: findings from a large pharmacy claims databaseDiabetes Care201538460460925573883
   PubMed Web of Science ®Google Scholar
• ChapmanRHPetrillaAABennerJSSchwartzJSTangSSPredictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort studyDrugs Aging2008251088589218808213
   PubMed Web of Science ®Google Scholar
• BennerJSChapmanRHPetrillaAATangSSRosenbergNSchwartzJSAssociation between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapyAm J Health Syst Pharm200966161471147719667004
   PubMed Web of Science ®Google Scholar
• NachegaJBParientiJJUthmanOALower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trialsClin Infect Dis20145891297130724457345
   PubMed Web of Science ®Google Scholar
• BlüherMKurzIDannenmaierSDworakMPill burden in patients with type 2 diabetes in Germany: subanalysis from the prospective, noninterventional PROVIL studyClin Diabetes2015332556125897184
   PubMedGoogle Scholar
• van GalenKANellenJFNieuwkerkPTThe effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysisAIDS Res Treat2014201496707325276422
   PubMedGoogle Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approachDiabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015 – a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• HoffmannTCLégaréFSimmonsMBShared decision making: what do clinicians need to know and why should they bother?Med J Aust20142011353924999896
   PubMed Web of Science ®Google Scholar
• BrandaMELeBlancAShahNDShared decision making for patients with type 2 diabetes: a randomized trial in primary careBMC Health Serv Res20131330123927490
   PubMed Web of Science ®Google Scholar
• WilsonSRStrubPBuistASShared treatment decision making improves adherence and outcomes in poorly controlled asthmaAm J Respir Crit Care Med2010181656657720019345
   PubMed Web of Science ®Google Scholar
• SapkotaSBrienJAGreenfieldJAslaniPA systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes: components and interventionsPLoS One2015106e012858126053004
   PubMed Web of Science ®Google Scholar
• DalsgaardNBBrøndenAVilsbøllTKnopFKCardiovascular safety and benefits of GLP-1 receptor agonistsExpert Opin Drug Saf201716335136328102093
   PubMed Web of Science ®Google Scholar
• MalmenäsMBouchardJRLangerJRetrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μgClin Ther201335679580723642290
   PubMed Web of Science ®Google Scholar
• CaiJWangYBaserOXieLChowWComparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United StatesJ Med Econ201619121175118627356271
   PubMed Web of Science ®Google Scholar
• JohnstonSSNguyenHFelberERetrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United StatesAdv Ther201431111119113325408484
   PubMed Web of Science ®Google Scholar
• QinLChenSFloodEGlucagon-like peptide-1 receptor agonist treatment attributes important to injection-naïve patients with type 2 diabetes mellitus: a multinational preference studyDiabetes Ther20178232133428155131
   PubMed Web of Science ®Google Scholar
• LeiterLAScottRAYeJCarrMCMedication compliance rates of weekly albiglutide vs. daily oral comparators in phase III trialsDiabetes201463Suppl 1A255
   Google Scholar
• AlatorreCLandóLFYuMTreatment patterns in patients with type 2 diabetes mellitus treated with GLP-1 receptor agonists: higher adherence and persistence with dulaglutide compared to exenatide QW and liraglutideDiabetes Obes Metab201719795396128181725
   PubMed Web of Science ®Google Scholar
• HauberABNguyenHPosnerJErvinCLaRueSKalsekarIPatient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetesValue Health2014173A255
   Web of Science ®Google Scholar
• GelhornHLPoonJLDaviesEWPaczkowskiRCurtisSEBoyeKSEvaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UKPatient Prefer Adherence201591611162226635470
   PubMed Web of Science ®Google Scholar
• GelhornHLStringerSMBrooksAPreferences for medication attributes among patients with type 2 diabetes mellitus in the UKDiabetes Obes Metab201315980280923464623
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAlbiglutide (Eperzan) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdfAccessed June 27, 2016
   Google Scholar
• European Medicines AgencyExenatide (Bydureon) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdfAccessed June 27, 2016
   Google Scholar
• European Medicines AgencyDulaglutide (Trulicity) [summary of product characteristics] Available from: http://ec.europa.eu/health/documents/community-register/2014/20141121130063/anx_130063_en.pdfAccessed June 27, 2016
   Google Scholar
• GallwitzBThe future of combination therapies of insulin with a glucagon-like peptide-1 receptor agonist in type 2 diabetes: is it advantageous?Eur Endocrinol20141029899
   Google Scholar
• VedtofteLKnopFKVilsbøllTEfficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetesExpert Opin Drug Saf201716338739628150516
   PubMed Web of Science ®Google Scholar
• MatfinGvan BruntKZimmermannAGThrelkeldRIgnautDASafe and effective use of the once weekly dulaglutide single-dose pen in injection-naive patients with type 2 diabetesJ Diabetes Sci Tech20159510711079
   PubMedGoogle Scholar
• BarbosaCDBalpMMKulichKGermainNRofailDA literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient Prefer Adherence20126394822272068
   PubMed Web of Science ®Google Scholar
• BestJHBoyeKSRubinRRCaoDKimTHPeyrotMImproved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice dailyDiabet Med200926772272819573122
   PubMed Web of Science ®Google Scholar
• ReaneyMYuMLakshmananMPechtnerVvan BruntKTreatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trialsDiabetes Obes Metab201517989690326095190
   PubMed Web of Science ®Google Scholar
• YuMvan BruntKVarnadoOJBoyeKSPatient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programmeDiabetes Obes Metab201618441942426691396
   PubMed Web of Science ®Google Scholar
• DaviesMPratleyRHammerMThomsenABCuddihyRLiraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metforminDiabet Med201128333333721309842
   PubMed Web of Science ®Google Scholar
• SchmidtWEChristiansenJSHammerMZychmaMJBuseJBPatient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label studyDiabet Med201128671572321388442
   PubMed Web of Science ®Google Scholar
• BlackburnDFSwidrovichJLemstraMNon-adherence in type 2 diabetes: practical considerations for interpreting the literaturePatient Prefer Adherence2013718318923487395
   PubMed Web of Science ®Google Scholar
• RobertsAWCrispGDEssermanDARothMTWeinbergerMFarleyJFPatterns of medication adherence and health care utilisation among patients with chronic disease who were enrolled in a pharmacy assistance programN C Med J201475331031825237868
   PubMedGoogle Scholar
• European Medicines AgencyExenatide (Byetta) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdfAccessed June 27, 2016
   Google Scholar
• European Medicines AgencyLiraglutide (Victoza) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdfAccessed June 27, 2016
   Google Scholar
• European Medicines AgencyLixisenatide (Lyxumia) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdfAccessed June 27, 2016
   Google Scholar
• CassimatisMKavanaghDJEffects of type 2 diabetes behavioural telehealth interventions on glycaemic control and adherence: a systematic reviewJ Telemed Telecare201218844745023209266
   PubMed Web of Science ®Google Scholar
• AlihaJMAsgariMKhayeriFRamazaniMFarajzadeganZJavaheriJGroup education and nurse-telephone follow-up effects on blood glucose control and adherence to treatment in type 2 diabetes patientsInt J Prev Med20134779780224049598
   PubMedGoogle Scholar